Johnson & Johnson in Talks to Acquire Ollin Biosciences for Up to $3.4 Billion

Johnson & Johnson (JNJ) is reportedly engaged in discussions to acquire privately held biotech firm Ollin Biosciences in a deal valued at up to $3.4 billion. According to reports from the Financial Times citing sources familiar with the matter, an official announcement regarding the acquisition could occur as early as Monday. The potential acquisition aligns with Johnson & Johnson's ongoing strategy to bolster its biotechnology pipeline through strategic M&A. If finalized, the deal would represent a significant capital deployment aimed at expanding the company's footprint in the specialized biotech sector.

By https://seekingalpha.com/user/51785401/bio · Seeking Alpha ·

Johnson & Johnson in Talks to Acquire Ollin Biosciences for Up to $3.4 Billion

Tickers: $JNJ

Topics: acquisition biotechnology pharmaceuticals

Read the full article at Seeking Alpha

Part of the story Johnson & Johnson in Talks to Acquire Ollin Biosciences for Up to $3.4 Billion (2 articles)

More World news